Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Immuno-oncology technology·2026
Same author

Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Rα mAb.

The journal of allergy and clinical immunology. In practice·2025
Same author

[The standardization of the diagnosis and treatment of infectious corneal epitheliopathy].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2025
Same author

Allergic Signature in Delayed Cross-Hypersensitivity to all Iodinated Contrast Media.

Allergy·2025
Same author

Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.

Revue neurologique·2024
Same author

Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].

Annals of oncology : official journal of the European Society for Medical Oncology·2024

相关实验视频

Updated: Jun 2, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K

简单的方法来预测淋巴细胞采集的化学抗原受体T细胞工程的简单方法.

O Hequet1, V Mialou2, F Cognasse3

  • 1Apheresis Unit, EFS (Etablissement Français du Sang) Auvergne-Rhône-Alpes, Centre Hospitalier Lyon Sud (South Lyon Hospital), HCL (Hospices Civils de Lyon), Pierre Bénite, France; CIRI, International Centre for Infectiology Research, University of Lyon, INSERM, U1111, France.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
|January 15, 2025
PubMed
概括

预测用于CAR T细胞治疗的T细胞采集现在更简单了. 一种新的方法可以根据前化淋巴细胞血液水平和经过处理的血液体积准确估计收集的T淋巴细胞.

关键词:
在CAR T细胞中,连续的单核细胞收集 (CMNC)半球体转化是一个半球体转化.估计 估计 估计免疫治疗是一种免疫疗法.淋巴细胞 淋巴细胞

更多相关视频

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

741
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

相关实验视频

Last Updated: Jun 2, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

741
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

科学领域:

  • 血液学 血液学 血液学
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 收集T淋巴细胞对于在不耐药的血液恶性瘤中使用CAR T细胞治疗至关重要.
  • 目前的方法缺乏标准化指导方针来预测T细胞产量.
  • T细胞产量受到前化淋巴细胞血液水平 (pcLBL) 和处理的血液体积 (BVs) 的影响.

研究的目的:

  • 定义和标准化用于预测T细胞收集的简单方法.
  • 为了计算处理的pcLBL和BV,无论采用什么设备.
  • 为了优化T细胞收集用于CAR T细胞工程.

主要方法:

  • 从400名患有非霍奇金淋巴瘤或多发性骨髓瘤的患者中进行了407次非 session的回顾性分析.
  • 收集效率 (CE1,CE2) 和中性粒细胞收集百分比的评估.
  • 对一个预测模型的评估,将pcLBL乘以处理的BV数量.

主要成果:

  • 淋巴细胞和T细胞的采集效率充足 (76 ± 15%和69 ± 15%).
  • 中性粒细胞的收集是最小的 (9 ± 12%).
  • 通过将pcLBL乘以2.5对每个处理的BV进行预测,可以预测T细胞的采集.

结论:

  • 已经建立了一种预测T细胞收集的简单方法.
  • 这种预测工具有助于非和血液学团队监测采集会话.
  • 该方法适用于不同类型的表平台和CAR T细胞技术.